Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
New Haven, CT
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
Meridian, ID
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
St Louis, MO
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
Anderson, SC
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
Anderson, SC
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
mi
from
Annandale, VA
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting
Tobacco Trials at St. Jude: Parent Willingness to Participate Among Families of Children With Cancer, Sickle Cell Disease, or Survivors of Childhood Cancer
Status: Enrolling
Updated:  3/5/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting
Tobacco Trials at St. Jude: Parent Willingness to Participate Among Families of Children With Cancer, Sickle Cell Disease, or Survivors of Childhood Cancer
Status: Enrolling
Updated: 3/5/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  3/7/2013
Children's of Alabama
mi
from
Birmingham, AL
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 3/7/2013
Children's of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  3/7/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 3/7/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  3/7/2013
University of Colorado at Denver
mi
from
Denver, CO
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 3/7/2013
University of Colorado at Denver
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  3/7/2013
Kosair Children's Hospital
mi
from
Louisville, KY
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 3/7/2013
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated:  3/7/2013
Johns Hopkins Medical
mi
from
Baltimore, MD
Evaluation of Spectra Optia RBC Exchange in Sickle Cell Patients
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
Status: Enrolling
Updated: 3/7/2013
Johns Hopkins Medical
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
A Study to Compare Analytes in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System
Status: Enrolling
Updated:  3/21/2013
Seventh Sense BIosystems
mi
from
Cambridge, MA
A Study to Compare Analytes in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System
Status: Enrolling
Updated: 3/21/2013
Seventh Sense BIosystems
mi
from
Cambridge, MA
Click here to add this to my saved trials
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease
Status: Enrolling
Updated:  4/30/2013
Targeted Medical Pharma
mi
from
Los Angeles, CA
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease
Status: Enrolling
Updated: 4/30/2013
Targeted Medical Pharma
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Trial of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis
Status: Enrolling
Updated:  5/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Trial of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis
Status: Enrolling
Updated: 5/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
Children's Hospital of Alabama
mi
from
Birmingham, AL
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
Children's Hospital of Wisconsin
mi
from
Wauwatosa, WI
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
Children's Hospital of Wisconsin
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
Children's Memorial Hospital-Northwestern University
mi
from
Chicago, IL
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
Children's Memorial Hospital-Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
Columbia University Medical Center
mi
from
New York, NY
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  5/31/2013
UT Southwestern University Hospital
mi
from
Dallas, TX
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 5/31/2013
UT Southwestern University Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Hepcidin and Anemia in Trauma
Hepcidin and Anemia in Trauma
Status: Enrolling
Updated:  6/12/2013
University of Michigan Health System
mi
from
Ann Arbor, MI
Hepcidin and Anemia in Trauma
Hepcidin and Anemia in Trauma
Status: Enrolling
Updated: 6/12/2013
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
Status: Enrolling
Updated:  6/25/2013
Seidman Cancer Center, University Hospitals
mi
from
Cleveland, OH
Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
Status: Enrolling
Updated: 6/25/2013
Seidman Cancer Center, University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase II Study of Umbilical Cord Blood Transplantation
A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
Status: Enrolling
Updated:  7/10/2013
Tufts Medical Center
mi
from
Boston, MA
A Phase II Study of Umbilical Cord Blood Transplantation
A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
Status: Enrolling
Updated: 7/10/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E
Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E
Status: Enrolling
Updated:  7/11/2013
University of Colorado Denver
mi
from
Aurora, CO
Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E
Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E
Status: Enrolling
Updated: 7/11/2013
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated:  7/29/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated: 7/29/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia
Status: Enrolling
Updated:  8/4/2013
Texas Children's Hospital
mi
from
Houston, TX
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia
Status: Enrolling
Updated: 8/4/2013
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia
Status: Enrolling
Updated:  8/4/2013
Houston Methodist Hospital
mi
from
Houston, TX
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia
Status: Enrolling
Updated: 8/4/2013
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System
Status: Enrolling
Updated:  9/3/2013
Seventh Sense Biosytems
mi
from
Cambridge, MA
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System
Status: Enrolling
Updated: 9/3/2013
Seventh Sense Biosytems
mi
from
Cambridge, MA
Click here to add this to my saved trials
Cognitive Rehabilitation in Sickle Cell Disease
Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  9/4/2013
Duke Child and Family Study Center
mi
from
Durham, NC
Cognitive Rehabilitation in Sickle Cell Disease
Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 9/4/2013
Duke Child and Family Study Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Southwestern Kidney Institute
mi
from
Tempe, AZ
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Southwestern Kidney Institute
mi
from
Tempe, AZ
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
North America Research Institute
mi
from
Azusa, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
North America Research Institute
mi
from
Azusa, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Central Nephrology Medical Group
mi
from
Bakersfield, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Central Nephrology Medical Group
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Pegasus Dialysis, LLC
mi
from
Bakersfield, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Pegasus Dialysis, LLC
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
California Institute of Renal Research
mi
from
La Mesa, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
California Institute of Renal Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Angel Kidney Care of Inglewood Dialysis Center
mi
from
Inglewood, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Angel Kidney Care of Inglewood Dialysis Center
mi
from
Inglewood, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Alliance Research Centers
mi
from
Laguna Hills, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Alliance Research Centers
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
St Vincent Dialysis Center
mi
from
Los Angeles, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
St Vincent Dialysis Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Academic Medical Research Institute
mi
from
Los Angeles, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Ronald Reagan Medical Center, Department of Pharmaceutical Services, Drug Information Center
mi
from
Los Angeles, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Ronald Reagan Medical Center, Department of Pharmaceutical Services, Drug Information Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Tower Nephrology Medical Group
mi
from
Los Angeles, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Tower Nephrology Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Kidney Research Center
mi
from
Lynwood, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Kidney Research Center
mi
from
Lynwood, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Valley Renal Medical Group
mi
from
Northridge, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Valley Renal Medical Group
mi
from
Northridge, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Ontario Dialysis, Inc.
mi
from
Ontario, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Ontario Dialysis, Inc.
mi
from
Ontario, CA
Click here to add this to my saved trials
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated:  9/17/2013
Apex Research of Riverside
mi
from
Riverside, CA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Status: Enrolling
Updated: 9/17/2013
Apex Research of Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials